ClinicalTrialsFinder
RecruitingNCT06806579

Atezolizumab-bevacizumab and Other Immunotherapies: Real-life Experience for Treatment of Hepatocellular Carcinoma

Sponsor

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Enrollment

1,000 participants

Start Date

Dec 21, 2022

Study Type

OBSERVATIONAL

Conditions

Hepatocellular Carcinoma (HCC)

Summary

\- Background Hepatocellular carcinoma (HCC), is the fifth most common cancer worldwide and the third leading cause of cancer-related death. In most cases (about 80%), HCC develops in a cirrhotic liver - a condition where the liver has been damaged over time, leading to scarring. This makes treatment more challenging. This study will gather and analyze data from patients treated in real-world settings to: 1. Understand the effectiveness and safety of new treatment combinations (e.g., atezolizumab-bevacizumab and durvalumab-tremelimumab). Identify the best treatment sequences for patients with advanced liver cancer. 2. Discover clinical and laboratory markers that predict treatment responses, helping personalize care and optimize outcomes. By addressing these questions, this study will provide valuable information to healthcare providers and guide future treatment decisions for patients with liver cancer.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This real-world observational study is tracking how well immunotherapy drug combinations — including atezolizumab plus bevacizumab — work in people with liver cancer (hepatocellular carcinoma) that cannot be treated with local procedures like ablation or embolization. **You may be eligible if...** - You have been diagnosed with liver cancer (hepatocellular carcinoma) that is not suitable for local treatment procedures - You are about to start or are already receiving first-line systemic therapy with atezolizumab-bevacizumab or another immunotherapy **You may NOT be eligible if...** - You are also receiving other anti-cancer treatments alongside immunotherapy - You have another active cancer at the same time Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(24)

Ospedali Riuniti Ancona, Via Conca, 71, 60126 Torrette AN

Torrette, AN, Italy

I.R.C.C.S. "S. De Bellis", Via Turi, 27, 70013 Castellana Grotte BA

Castellana Grotte, BA, Italy

AUSL Bologna Via Castiglione 15 40136 Bologna BO

Bologna, BO, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna (Oncology Unit), Bologna, BO 40136

Bologna, BO, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna (Semiotics Unit)

Bologna, BO, Italy

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Bologna, BO, Italy

Azienda Ospedaliera di Rilievo Nazionale e di Alta Specializzazione "Garibaldi, Piazza Santa Maria di Gesù, 5, 95123 Catania CT

Catania, CT, Italy

Ospedali Riuniti. Viale Pinto Luigi, 1, 71122 Foggia FG.

Foggia, FG, Italy

Ospedali Riuniti. Viale Pinto Luigi, 1, 71122 Foggia FG

Foggia, FG, Italy

AOU Careggi. Largo G. Alessandro Brambilla, 3. 50134 Firenze FI

Florence, FI, Italy

Policlinico di Modena Via del Pozzo, 71, 41125 Modena MO

Modena, Missouri, Italy

Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico. via Francesco Sforza, 28 - 20122 Milano.

Milan, MI, Italy

ASST Grande Ospedale Metropolitano Niguarda, Piazza dell'Ospedale Maggiore, 3, 20162 Milano

Milan, MI, Italy

Humanitas Research Hospital. Via Alessandro Manzoni, 56, 20089 Rozzano MI

Rozzano, MI, Italy

Azienda Ospedaliero- Universitaria Paolo Giaccone. Via Liborio Giuffrè, 5, 90127 Palermo

Palermo, PA, Italy

Istituto Oncologico Veneto. Via Gattamelata, 64, 35128 Padova PD

Padova, PD, Italy

AOU Pisana. Via Roma 67. 56126 Pisa PI

Pisa, PI, Italy

Ospedale degli Infermi Viale Stradone, 9 48018 Faenza (RA)

Faenza, RA, Italy

IRCCS Santa Maria Nuova Viale Risorgimento, 80, 42123 Reggio Emilia

Reggio Emilia, RE, Italy

Policlinico Gemelli. Largo Agostino Gemelli, 8, 00168 Roma RM

Roma, RM, Italy

Azienda sanitaria universitaria Friuli Centrale, Piazzale Santa Maria della Misericordia, 15 33100 Udine (UD)

Udine, UD, Italy

Azienda Ospedaliera Universitaria Integrata di Verona. Piazzale Aristide Stefani, 1, 37126 Verona VR

Verona, VR, Italy

P.O. Ospedale del Mare. Via Enrico Russo, 11, 80147 Napoli NA

Naples, Italy

Azienda Ospedaliero- Universitaria Maggiore della Carità, Padiglione G, L.go Bellini, 28100 Novara NO

Novara, Italy

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06806579

Related Trials

A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

NCT0729107650 locations

A Phase 1 Study of the Safety and Tolerability of CTX-10726

NCT074198414 locations

Computer Guided Microwave Liver Ablation

NCT072268692 locations

DEB-TACE vs cTACE in HCC After TIPS

NCT073228481 location

Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer

NCT070751202 locations